Incyte’s $750 million buyout of Escient Pharmaceuticals is in a rough patch as a mid-stage chronic hives candidate was flagged with safety … ...
The US Food and Drug Administration (FDA) has accepted a resubmission of the supplemental Biologics License Application for dupilumab for the treatment of chronic spontaneous urticaria (CSU ...
The addition of dupilumab significantly reduced itching and hives compared with placebo in patients with chronic spontaneous urticaria (CSU) that was uncontrolled with H1-antihistamines ...
In rare cases, endometriosis may spread to the lymph nodes and cause swelling. However, if a person with endometriosis has lymph node swelling, it is more likely due to a viral infection such as ...
This causes sudden and debilitating hives and swelling on the skin ... for six type II inflammatory diseases, namely severe chronic rhinosinusitis with nasal polyposis, severe asthma, moderate ...
Jasper Therapeutics, Inc.'s Briquilimab shows promise in treating chronic urticaria and asthma, with potential market approval by 2027, offering significant revenue opportunities in large ...